Condition
Agitation in Dementia, Including Alzheimer's Disease
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 3 (1)
Trial Status
Terminated1
Enrolling By Invitation1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06451952Not ApplicableRecruitingPrimary
Virtual Darkness Theraphy for Agitation in Dementia
NCT06216275Not ApplicableEnrolling By Invitation
Enhancing Calm in Arab Elderly With Dementia
NCT02817906Phase 3TerminatedPrimary
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
Showing all 3 trials